Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLP-IL-31
- Development stage
- Preclinical
- Lead developer
- Saiba Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
VLP-IL-31 is a virus-like particle (VLP)-based conjugate vaccine developed by Saiba Biotech for the treatment of atopic dermatitis. The vaccine consists of the Interleukin-31 (IL-31) antigen covalently coupled to VLPs derived from the cucumber mosaic virus (CuMV), which incorporate universal T-cell epitopes to enhance immunogenicity. By inducing the production of endogenous neutralizing antibodies against IL-31—a key cytokine responsible for pruritus (itching) and skin inflammation—the vaccine aims to provide long-term relief from the symptoms of atopic dermatitis. While the technology has been validated in veterinary models for canine atopic dermatitis, the human candidate is currently in preclinical development under a licensing agreement with Allergy Therapeutics.
- Other names
- IL-31-VLP-based conjugate vaccineIL31-VLP-based conjugate vaccineIL 31-VLP-based conjugate vaccineCMV-VLP-IL-31 vaccineCMV-VLP-IL31 vaccineCMV-VLP-IL 31 vaccine
02
Targets
IL31 (IL-31)
Beyond the preview
Go deeper on VLP-IL-31.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLP-IL-31.